← All candidates
24 insider filings on record.
28 filings on record.
REPLReplimune Group, Inc.
NasdaqGS · Healthcare · $1.22B
$12.96
-0.54% · Sep 16
24 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 15 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.22B
Float
67.7M
72% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
19 more transactions on Pro →Context
Wall St
$4.67 avg target
-64.0% vs today · 6 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q4 '25−$0.77 act+$0.05
Q3 '25−$0.90 act−$0.11
Q2 '25−$0.95 act−$0.15
Q1 '25−$0.82 act−$0.13
Coverage
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo DrugZacks · 06-01Why Is REPL Stock Gaining In Pre-Market Today?Stocktwits · 06-01How Replimune’s Drug Got Third Chance After White House InterventionThe Wall Street Journal · 05-30REPL Stock Shot Up 80% Today – What’s The Deal With FDA?Stocktwits · 05-29
The file stays open
28 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice